Immune checkpoint inhibition in ovarian cancer - open access

Immune checkpoint inhibition in ovarian cancer

Navigate This Article

1. Top
2. Abstract
3. Introduction
4. The clinical significance of the local immune status in ovarian cancer
5. The B7/CTLA-4 signal
6. B7/CTLA-4 signal inhibitors
7. PD-1/PD-L1 ligand signaling
8. PD-1/PD-L1 signaling in pre-clinical cancer models
9. PD-1/PD-L1 signaling in clinical studies of cancer
10. Clinical applications of PD-1 inhibitors in cancer
11. Clinical applications of PD-1 inhibitors in ovarian cancer
12. Clinical issues related to PD-1 inhibitors for ovarian cancer
13. Conclusions
14. Funding
15. Acknowledgements
16. References 

Conclusions 
The early phase of clinical trials of immune checkpoint inhibitors for ovarian cancer have shown the manageable safety profile (17–20) and have demonstrated a dramatic durable anti-tumor response in a certain population of the patients with a 1-year schedule of nivolumab treatment, following no adjuvant anti-tumor treatment (89). Therefore, not only to explore the predictive biomarkers of responders and to find a good combination therapy but also to conduct a clinical trial to decide the maximum anti-tumor effect with a minimum treatment period of immune checkpoint inhibitors may be a next turning point to enhance the value of immune checkpoint inhibitors for ovarian cancer.